PHILADELPHIA - Researchers at the National Cancer Institute have identified a gene that may play a role in breast cancer metastasis to the brain, according to a report in Molecular Cancer Research, a journal of the American Association for Cancer Research.
Diane Palmieri, Ph.D., a staff scientist at the NCI, said Hexokinase 2 overexpression was more highly expressed in brain metastasis in patients with breast cancer than in primary breast tumors.
"Importantly, this study was conducted in human tissue rather than animal models, so we are able to extrapolate data without the problems inherent in animal studies," said Palmieri.
Brunhilde Felding-Habermann, Ph.D., an associate professor at The Scripps Research Institute, said the findings are a major step forward in potential breast cancer treatments.
"Improvements in breast cancer therapy have made prognoses like brain metastasis a growing problem, and this research points to a potential target for future therapies," said Felding-Habermann.
Researchers performed analyses on both primary tumors and brain metastases. They found higher levels of Hexokinase 2 in brain metastases compared with unlinked primary tumors. Among resected brain metastases, these higher levels of Hexokinase 2 were linked with worse survival. The median survival for patients with high levels of Hexokinase 2 expression in their brain metastasis was 9.6 months compared with 17.5 months for those with lower expression.
Palmieri said that Hexokinase 2 plays a key role in glucose metabolism, which provides the energy tumors need to grow. It also impacts the cell survival process, apoptosis.
"Potential therapies would need to turn off this gene and thus starve the tumor of its growth potential," said Palmieri.
Subscribe to the AACR News Feed: http://feeds.
Subscribe to the Molecular Cancer Research RSS Feed: http://mcr.
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 28,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and nearly 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.